From screening to enrollment: Mastering the start-up in precision oncology

By Csilla Szalay, Senior Feasibility & Strategy Leader
Laura Cerny, Senior Director of Launch Excellence
Charlotte Moser, M.D., Ph.D., M.B.A., Chief Medical Officer

Published on: Jun 1, 2026

6 min

Precision oncology trials face unique operational challenges in the study start-up phase because patients must be screened for an exact molecular profile. Determining eligibility typically requires advanced genetic testing and imaging. Therefore, enrollment can have long lead times, and sponsors must anticipate and solve problems early to meet development deadlines. Here are three challenges sponsors face and how they can overcome them.